Adial Pharmaceuticals reported on July 9, 2025, that after raising approximately $3.6 million through a new stock offering on June 18, 2025, it believes it has regained compliance with Nasdaq's stockholders’ equity requirement of $2,500,000, following a previous non-compliance notice due to equity of $2,126,662 as of March 31, 2025.